{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-053541","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.698476+00:00","generated_at":"2026-05-24T21:28:07.440278+00:00","sec_items":["1.01","3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pliant Therapeutics adopts limited-duration poison pill; rights expire March 11, 2026","bullets":["Board adopted rights agreement on March 12, 2025; dividend of one right per share to holders of record March 25, 2025.","Rights become exercisable at $12.64/right if a person acquires 10% (20% for passive investors) of stock without approval.","Upon trigger, holders (excluding acquiring person) can buy shares at 50% discount; rights expire March 11, 2026.","Existing holders above thresholds are grandfathered but cannot increase ownership without losing grandfathered status.","Board may redeem rights at $0.001 each or exchange for common stock prior to trigger."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-053541","json":"https://secwatch.observer/filing/0001193125-25-053541.json","markdown":"https://secwatch.observer/filing/0001193125-25-053541.md","text":"https://secwatch.observer/filing/0001193125-25-053541.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000119312525053541/0001193125-25-053541-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000119312525053541/d815684d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:28:07.440278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0e1051aecb81c05c9e1a78c26fc9ea77bb0222f7","claim":"PLIANT THERAPEUTICS, INC.: Adopted Certificate of Designation for Series A Junior Participating Preferred Stock in connection with stockholder rights agreement (effective 2025-03-13).","evidence_excerpt":"In connection with the adoption of the Rights Agreement described in Item 3.03 of this Current Report, the Board approved a Certificate of Designation of Series A Junior Participating Preferred Stock, which designates the rights, preferences and privileges of 300,000 shares of a series of the Company’s preferred stock, par value $0.0001 per share, designated as Series A Junior Participating Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000119312525053541/0001193125-25-053541-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-03-13"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}